ABVC BioPharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ABVC BioPharma, Inc. (ECOC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 2.79% for the 12-month period ending 2023-12-31, per its 10-Q filed 2024-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2024-11-14
- ABVC BioPharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 1.13%, a 197.37% increase from fiscal 2020.
- ABVC BioPharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.38%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|
| 2023-12-31 | 2.79% 10-Q · filed 2024-08-14 |
| 2022-12-31 | 2.79% 10-Q · filed 2024-11-14 |
| 2021-12-31 | 1.13% 10-K · filed 2023-03-31 |
| 2020-12-31 | 0.38% 10-K · filed 2022-03-31 |
| 2019-12-31 | 0.38% 10-Q · filed 2021-05-10 |
| 2011-12-31 | 1.03% 10-Q/A · filed 2012-08-20 |